US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

18.36

+0.61993.49%

Volume:17.82K

Turnover:325.77K

Market Cap:108.33M

PE:- -

High:18.36

Open:18.31

Low:18.11

Close:17.74

52wk High:21.50

52wk Low:14.38

Shares:5.90M

Float Shares:5.90M

Volume Ratio:0.53

T/O Rate:0.30%

Dividend:0.71

Dividend Rate:3.89%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy

MT Newswires Live

CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors

Wuxi Biologics (Cayman) Stock Falls 4.7% in Hong Kong

Daiwa Raises CSPC Pharma Target Price to HK$11.2 on In-Line Interim Results

BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating

UBS Lifts CSPC Pharma Price Target to HK$11.80, Reiterates Buy Rating

Goldman Sachs Adjusts CSPC Pharma Target Price Upward While Retaining Buy Stance

CSPC Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Simply Wall St.

China's Haohai Biological H1 Revenue Falls, Partly Hurt by End of Brighten Optix Distribution

TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million

UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50

MT Newswires Live

Goldman Sachs Raises CSPC Pharma Price Target to HK$12.56, Reaffirms Buy Rating

Wuxi Biologics (Cayman) Stock Rallies 2.7% in Hong Kong

CSPC Pharmaceutical Group Stock Falls 3.5% in Hong Kong, Underperforms Competitors

美银证券上调石药集团目标价至8.6港元，维持“跑输大市”评级

Akeso Says China NMPA Clears Phase I Trial for B7-H3 ADC Ak157d1 in Solid Tumors

Akeso's Ak157d1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

THOMSON REUTERS

Morgan Stanley Raises CSPC Pharma Target Price to HK$12, Maintains Overweight Rating

Moderna's Personalized mRNA Vaccine Achieves First Success, Chinese Innovators Line Up

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/KURE/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":18.3599,"timestamp":1789406223082,"preClose":17.74,"halted":0,"volume":17818,"delay":0,"changeRate":0.03494363021420526,"floatShares":5900168,"shares":5900168,"eps":0,"marketStatus":"Trading","change":0.6199,"latestTime":"09-14 13:26:04 EDT","open":18.31,"high":18.3599,"low":18.1101,"amount":325772.961934,"amplitude":0.014081,"askPrice":18.35,"askSize":20,"bidPrice":18.18,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":17.74,"sharesOutstanding":4750002,"nav":17.75,"aum":104708978.23,"dividendRate":0.038933,"bidAskSpread":0.008219,"postHourTrading":{"tag":"盘后","latestPrice":17.8,"preClose":17.74,"latestTime":"19:30 EDT","volume":110,"amount":1957.48,"timestamp":1789169406504,"change":0.06,"changeRate":0.003382,"amplitude":0.003382},"volumeRatio":0.525044,"impliedVol":0.2654,"impliedVolPercentile":0.5179},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5900168,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.525044,"shares":5900168,"dividePrice":0.7148,"high":18.3599,"amplitude":0.014081,"preClose":17.74,"low":18.1101,"week52Low":14.3797,"pbRate":"--","week52High":21.5,"institutionHeld":0,"latestPrice":18.3599,"committee":0.923077,"eps":0,"divideRate":0.038933,"volume":17818,"delay":0,"ttmEps":0,"open":18.31,"prevYearClose":17.04,"prevWeekClose":17.74,"prevMonthClose":18.54,"prevQuarterClose":15.747,"fiveDayClose":18.9,"twentyDayClose":18.43,"sixtyDayClose":14.56},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661273772","title":"WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273772","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273772?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:22","pubTimestamp":1787570557,"startTime":"0","endTime":"0","summary":"WuXi XDC FY26 H1 net profit rises 9.7% to RMB 818 million; revenue climbs 37% to RMB 3.7 billionWuxi XDC Cayman posted revenue of RMB 3.7 billion, up 37% year over year, for the six months ended June ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL6G2blf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0588546209.SGD","LU0516423174.USD","LU0051755006.USD","LU0572944931.SGD","LU0307460666.USD","LU0359202008.SGD","LU0348825331.USD","LU2488822045.USD","LU0823426308.USD","LU0140636845.USD","LU0819121731.USD","LU0456846285.SGD","SG9999014674.SGD","LU0327786744.USD","LU0516422440.USD","BK1610","BK1521","LU0708995583.HKD","LU0979878070.USD","02268","LU0823426480.USD","LU1242518857.USD","LU1688375341.USD","LU0039217434.USD","LU0417516738.SGD","BK1576","LU0326950275.SGD","LU0516423091.SGD","LU0348735423.USD","BK1589","KURE","LU0043850808.USD","LU0052750758.USD","LU0516422366.SGD","IE00B0JY6N72.USD","LU0320764599.SGD","LU0456827905.SGD","LU0417516902.SGD","SG9999002562.SGD","LU1880383366.USD","02269","LU0856984785.SGD","LU1242518931.SGD","LU0029874061.USD","LU0359201612.USD","BK1141","LU0128526141.USD","LU0181495838.USD","LU2039709279.SGD","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273445","title":"Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273445","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273445?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:12","pubTimestamp":1787569969,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) has an average rating of buy and mean price target of HK$12.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0326950275.SGD","LU2039709279.SGD","IE00BZ08YR35.GBP","IE0008368742.USD","LU1951186391.HKD","LU1226288253.USD","LU1960683339.HKD","LU1152091168.USD","LU0072913022.USD","01093","LU0314109678.HKD","LU1226288170.HKD","IE00BZ08YT58.USD","LU1226287529.USD","LU1813983027.USD","IE00B543WZ88.USD","IE00B031HY20.USD","IE00BZ08YS42.EUR","LU0067412154.USD","LU0140636845.USD","LU1328277881.USD","LU1993786604.SGD","LU1152091754.HKD","LU1226287875.USD","IE0008369823.USD","HK0000165453.HKD","LU0501845795.SGD","LU1807302812.USD","LU0315179316.USD","BK1521","LU1226287792.SGD","BK1191","KURE","BK1515","LU0880133367.SGD","LU1008478684.HKD","IE00B5MMRT66.SGD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661497221","title":"CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2661497221","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661497221?lang=en_us&edition=fundamental","pubTime":"2026-08-24 16:32","pubTimestamp":1787560320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. rose 2.2% to 9.40 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.9% to 25517.33.CSPC Pharmaceutical Group Ltd. closed 19% short of its 52-week high of HK$11.63, which the company achieved Sept. 9.The stock outperformed some of its competitors, as Sino Biopharmaceutical Ltd. fell 0.3%, SSY Group Ltd. fell 0.4%, and United Laboratories International Holdings Ltd. fell 0.7%.Trading volume totaled 141.6 million shares, compared to the 50-day average of 98.7 million shares.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1807302812.USD","LU1226288253.USD","IE00B031HY20.USD","LU0501845795.SGD","LU1008478684.HKD","LU2039709279.SGD","LU0067412154.USD","IE00BZ08YT58.USD","LU0072913022.USD","SG9999004220.SGD","LU1152091754.HKD","IE00BZ08YS42.EUR","KURE","LU0140636845.USD","LU1226288170.HKD","LU1813983027.USD","IE0008369823.USD","01093","IE00B5MMRT66.SGD","LU0314109678.HKD","LU0880133367.SGD","BK1515","HK0000165453.HKD","LU1328277881.USD","BK1191","LU1152091168.USD","IE00BZ08YR35.GBP","LU1226287529.USD","LU1226287792.SGD","LU1951186391.HKD","IE00B543WZ88.USD","IE0008368742.USD","BK1521","LU1993786604.SGD","LU0326950275.SGD","LU1226287875.USD","LU0315179316.USD","LU1960683339.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661221146","title":"Wuxi Biologics (Cayman) Stock Falls 4.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2661221146","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661221146?lang=en_us&edition=fundamental","pubTime":"2026-08-24 16:30","pubTimestamp":1787560200,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. slipped 4.7% to 48.60 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.9% to 25517.33.The stock's fall snapped a two-day winning streak.Wuxi Biologics  Inc. closed 5.7% below its 52-week high of HK$51.55, which the company achieved Aug. 20.Trading volume totaled 43.8 million shares, compared to the 50-day average of 35.0 million shares.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880383366.USD","LU1720050803.USD","LU0516423091.SGD","LU0516423174.USD","LU0572944931.SGD","LU0708995583.HKD","LU0326950275.SGD","LU1794554557.SGD","LU1242518931.SGD","LU0043850808.USD","IE00B0JY6N72.USD","LU0140636845.USD","LU0359202008.SGD","LU0456846285.SGD","LU0348825331.USD","LU0320764599.SGD","LU0823426308.USD","BK1521","LU0128526141.USD","BK1589","LU0181495838.USD","LU0348735423.USD","LU0516422366.SGD","LU0516422952.EUR","LU3063872942.SGD","SG9999002463.SGD","BK1610","LU0307460666.USD","SG9999002562.SGD","LU0823426480.USD","BK1576","LU0588546209.SGD","LU0856984785.SGD","LU0979878070.USD","LU1688375341.USD","LU0359201612.USD","02269","LU0417516738.SGD","LU0819121731.USD","LU0052750758.USD","LU0051755006.USD","KURE","LU0516422440.USD","LU2039709279.SGD","LU0456827905.SGD","LU0327786744.USD","LU0029874061.USD","LU0417516902.SGD","LU0039217434.USD","LU1242518857.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106235404","title":"Daiwa Raises CSPC Pharma Target Price to HK$11.2 on In-Line Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1106235404","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106235404?lang=en_us&edition=fundamental","pubTime":"2026-08-24 15:46","pubTimestamp":1787557578,"startTime":"0","endTime":"0","summary":"Daiwa has issued a research report noting that CSPC Pharma (01093) posted a 40.1% year-on-year increase in interim revenue to RMB 18.59 billion, aligning with its earlier business guidance and the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","IE0008368742.USD","BK1515","LU0326950275.SGD","HK0000165453.HKD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU0140636845.USD","LU1993786604.SGD","LU0315179316.USD","BK1191","BK1521","LU0880133367.SGD","LU1951186391.HKD","IE00BZ08YT58.USD","LU1226287792.SGD","LU1960683339.HKD","01093","LU1813983027.USD","SG9999004220.SGD","EWH","LU1152091168.USD","LU1226288170.HKD","LU1226287529.USD","LU1226288253.USD","LU1008478684.HKD","LU1226287875.USD","LU0067412154.USD","LU0501845795.SGD","LU1152091754.HKD","KURE","LU1328277881.USD","LU2039709279.SGD","IE00B5MMRT66.SGD","LU0072913022.USD","IE0008369823.USD","LU1807302812.USD","LU0314109678.HKD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128964959","title":"BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1128964959","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128964959?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:50","pubTimestamp":1787460626,"startTime":"0","endTime":"0","summary":"BofA Securities has released a research report indicating that CSPC PHARMA (01093) saw its total revenue and attributable net profit surge by 40.1% and 139.2% year-on-year, respectively, reaching RMB...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","BK1521","KURE","LU1226287529.USD","HK0000165453.HKD","IE0008369823.USD","IE00BZ08YT58.USD","LU1993786604.SGD","IE0008368742.USD","IE00B5MMRT66.SGD","LU1152091754.HKD","LU0880133367.SGD","LU0072913022.USD","LU1807302812.USD","BK1191","IE00B543WZ88.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU0314109678.HKD","LU1226287792.SGD","LU1152091168.USD","LU0067412154.USD","BK1515","LU1226288253.USD","LU1960683339.HKD","IE00B031HY20.USD","01093","161027","EWH","LU0140636845.USD","LU1328277881.USD","LU0326950275.SGD","LU0315179316.USD","LU1008478684.HKD","LU1226287875.USD","LU0501845795.SGD","LU1813983027.USD","LU1226288170.HKD","LU1951186391.HKD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110238919","title":"UBS Lifts CSPC Pharma Price Target to HK$11.80, Reiterates Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1110238919","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110238919?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:40","pubTimestamp":1787460024,"startTime":"0","endTime":"0","summary":"UBS has released a research report reiterating its \"Buy\" rating on CSPC PHARMA (01093) and raising its target price from HK$10.9 to HK$11.8. The adjustment reflects the company's increased R&D...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1226287875.USD","LU1951186391.HKD","IE00B031HY20.USD","IE00BZ08YS42.EUR","BK1521","LU0326950275.SGD","LU0067412154.USD","LU0501845795.SGD","LU1226288253.USD","LU0140636845.USD","LU1328277881.USD","IE00B5MMRT66.SGD","HK0000165453.HKD","LU0314109678.HKD","LU2039709279.SGD","BK1515","LU1152091754.HKD","IE00B543WZ88.USD","LU1226287529.USD","SG9999004220.SGD","KURE","LU1008478684.HKD","01093","LU0880133367.SGD","LU1813983027.USD","LU0315179316.USD","IE0008368742.USD","IE0008369823.USD","LU0072913022.USD","LU1226287792.SGD","EWH","LU1226288170.HKD","BK1191","LU1807302812.USD","LU1993786604.SGD","LU1960683339.HKD","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162911841","title":"Goldman Sachs Adjusts CSPC Pharma Target Price Upward While Retaining Buy Stance","url":"https://stock-news.laohu8.com/highlight/detail?id=1162911841","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162911841?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:30","pubTimestamp":1787459445,"startTime":"0","endTime":"0","summary":"Goldman Sachs has released a research note reaffirming its \"Buy\" rating on CSPC Pharma (01093), while raising its profit forecasts for the 2026 to 2028 period by 0.2% to 1.7%. The investment bank has...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0501845795.SGD","BK1515","LU1226287529.USD","LU1993786604.SGD","LU1813983027.USD","IE00B031HY20.USD","LU1951186391.HKD","IE0008369823.USD","IE00BZ08YT58.USD","LU0067412154.USD","LU1226287792.SGD","HK0000165453.HKD","BK1521","KURE","LU1807302812.USD","IE00B543WZ88.USD","LU0326950275.SGD","SG9999004220.SGD","LU0072913022.USD","LU1328277881.USD","IE0008368742.USD","LU0314109678.HKD","LU0315179316.USD","01093","LU1008478684.HKD","LU0140636845.USD","LU1152091168.USD","LU1152091754.HKD","LU1226287875.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","LU2039709279.SGD","IE00BZ08YR35.GBP","BK1191","LU0880133367.SGD","LU1960683339.HKD","LU1226288253.USD","IE00BZ08YS42.EUR","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661217309","title":"CSPC Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2661217309","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661217309?lang=en_us&edition=fundamental","pubTime":"2026-08-23 08:56","pubTimestamp":1787446588,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited ( HKG:1093 ) defied analyst predictions to release its half-year results, which were...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-limited-beat-analyst-estimates-see","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-limited-beat-analyst-estimates-see","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BZ08YT58.USD","DECU","LU1226287875.USD","LU1328277881.USD","RGLO","LU0501845795.SGD","LU0067412154.USD","LU1993786604.SGD","LU1960683339.HKD","LU0140636845.USD","IE0008369823.USD","LU0315179316.USD","LU1008478684.HKD","VOTE","IE00BZ08YR35.GBP","JOYT","LU1152091168.USD","LU1226287792.SGD","IE00B543WZ88.USD","LU0880133367.SGD","IE0008368742.USD","LU1226288170.HKD","PMDE","SG9999004220.SGD","LU0072913022.USD","BK1521","KURE","LU1152091754.HKD","LU1951186391.HKD","LU1807302812.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU1226288253.USD","LU0314109678.HKD","LU2039709279.SGD","GXDW","IE00BZ08YS42.EUR","VGFPF","01093","LU1226287529.USD","HK0000165453.HKD","BK1191","FEBU","LU1813983027.USD","LU0326950275.SGD","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661932892","title":"China's Haohai Biological H1 Revenue Falls, Partly Hurt by End of Brighten Optix Distribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2661932892","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661932892?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:25","pubTimestamp":1787318735,"startTime":"0","endTime":"0","summary":"China's Haohai Biological H1 revenue falls, partly hurt by end of Brighten Optix distributionOverviewChina biomedical products maker's half-year revenue fell 9.8% yr/yr to RMB1.17 blnNet profit attrib","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0EM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","LU1226287792.SGD","IE00B031HY20.USD","LU0326950275.SGD","LU1226287529.USD","SG9999004220.SGD","LU1152091168.USD","688366","LU1993786604.SGD","LU1960683339.HKD","06826","LU0072913022.USD","IE0008368742.USD","IE00B5MMRT66.SGD","IE0008369823.USD","IE00B543WZ88.USD","LU1951186391.HKD","IE00BZ08YR35.GBP","LU2039709279.SGD","LU1152091754.HKD","LU1807302812.USD","LU1226288170.HKD","LU1008478684.HKD","LU0314109678.HKD","BK1521","01093","BK1161","LU0880133367.SGD","IE00BZ08YS42.EUR","LU1328277881.USD","BK1515","LU0501845795.SGD","LU0067412154.USD","BK1593","LU1813983027.USD","KURE","LU0315179316.USD","BK0239","LU1226287875.USD","BK0251","LU1226288253.USD","LU0140636845.USD","HK0000165453.HKD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260315","title":"TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260315","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260315?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:47","pubTimestamp":1787312862,"startTime":"0","endTime":"0","summary":"TOT Biopharm FY26 H1 net loss swings to RMB 59 million; revenue drops 49.7% to RMB 246 millionTOT BioPharm posted a net loss of RMB 59 million for the six months ended June 30, swinging from profit.Re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL4m4SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","LU0456827905.SGD","LU0320764599.SGD","BK1589","LU0359201612.USD","LU0417516902.SGD","LU0572944931.SGD","LU0516423091.SGD","LU1688375341.USD","LU1242518857.USD","SG9999002463.SGD","LU0307460666.USD","LU0417516738.SGD","LU0052750758.USD","LU1720050803.USD","SG9999002562.SGD","BK1576","LU1794554557.SGD","LU0516422952.EUR","LU0128526141.USD","LU0979878070.USD","LU0051755006.USD","LU0516422440.USD","LU1880383366.USD","LU0348735423.USD","LU3063872942.SGD","LU0856984785.SGD","LU0823426308.USD","LU0819121731.USD","02269","BK1521","BK1161","LU0029874061.USD","LU0327786744.USD","LU0140636845.USD","KURE","LU0359202008.SGD","IE00B0JY6N72.USD","LU0588546209.SGD","LU0043850808.USD","LU0181495838.USD","BK1574","01875","LU0823426480.USD","LU1242518931.SGD","LU0456846285.SGD","LU0516422366.SGD","LU0348825331.USD","LU0039217434.USD","LU0516423174.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661646202","title":"UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2661646202","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661646202?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:26","pubTimestamp":1787307972,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) has an average rating of overweight and mean price target of HK$12.07, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0072913022.USD","IE00B031HY20.USD","HK0000165453.HKD","IE00BZ08YR35.GBP","LU0314109678.HKD","IE00B543WZ88.USD","LU1813983027.USD","LU1960683339.HKD","IE00BZ08YT58.USD","IE0008369823.USD","LU1993786604.SGD","LU0140636845.USD","LU1807302812.USD","IE00B5MMRT66.SGD","LU1226287875.USD","LU2039709279.SGD","LU0880133367.SGD","SG9999004220.SGD","01093","LU1152091754.HKD","LU1226287792.SGD","LU0315179316.USD","LU1328277881.USD","BK1191","BK1515","IE0008368742.USD","LU1226288253.USD","LU1951186391.HKD","LU1226288170.HKD","LU1226287529.USD","LU1008478684.HKD","LU0326950275.SGD","LU0501845795.SGD","LU0067412154.USD","KURE","IE00BZ08YS42.EUR","LU1152091168.USD","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191293609","title":"Goldman Sachs Raises CSPC Pharma Price Target to HK$12.56, Reaffirms Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1191293609","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191293609?lang=en_us&edition=fundamental","pubTime":"2026-08-21 17:20","pubTimestamp":1787304047,"startTime":"0","endTime":"0","summary":"Goldman Sachs has released a research report reaffirming its \"Buy\" rating on CSPC Pharma (01093), while lifting the target price from HK$12.14 to HK$12.56. The firm has also raised its earnings...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0501845795.SGD","EWH","IE00B5MMRT66.SGD","LU2039709279.SGD","BK1191","IE00BZ08YS42.EUR","LU1152091168.USD","LU0067412154.USD","LU1226287792.SGD","LU0072913022.USD","LU1226287875.USD","IE00B031HY20.USD","LU1807302812.USD","01093","BK1521","KURE","LU1152091754.HKD","LU1813983027.USD","SG9999004220.SGD","LU1951186391.HKD","LU0880133367.SGD","LU0315179316.USD","IE00B543WZ88.USD","LU0326950275.SGD","IE00BZ08YR35.GBP","IE0008368742.USD","LU1226288170.HKD","LU0314109678.HKD","LU1960683339.HKD","LU1993786604.SGD","LU1226287529.USD","BK1515","IE00BZ08YT58.USD","LU0140636845.USD","LU1226288253.USD","IE0008369823.USD","LU1008478684.HKD","LU1328277881.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661029263","title":"Wuxi Biologics (Cayman) Stock Rallies 2.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2661029263","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661029263?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:32","pubTimestamp":1787301120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rose 2.7% to 51.00 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.2% to 26009.46.This was the stock's second consecutive day of gains.Wuxi Biologics  Inc. closed 1.1% short of its 52-week high of HK$51.55, which the company achieved Aug. 20.Trading volume totaled 37.2 million shares, compared to the 50-day average of 35.0 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","LU0456827905.SGD","LU0320764599.SGD","BK1589","LU0359201612.USD","LU0417516902.SGD","LU0572944931.SGD","LU0516423091.SGD","LU1688375341.USD","LU1242518857.USD","SG9999002463.SGD","BK1141","LU0307460666.USD","LU0417516738.SGD","LU0052750758.USD","LU1720050803.USD","SG9999002562.SGD","BK1576","LU1794554557.SGD","BK1610","LU0516422952.EUR","LU0128526141.USD","LU0979878070.USD","LU0051755006.USD","LU0516422440.USD","LU0708995583.HKD","LU1880383366.USD","LU0348735423.USD","LU3063872942.SGD","LU0856984785.SGD","LU0823426308.USD","LU0819121731.USD","02269","BK1521","LU0029874061.USD","LU0327786744.USD","LU0140636845.USD","KURE","LU0588546209.SGD","IE00B0JY6N72.USD","LU2039709279.SGD","LU0043850808.USD","LU0181495838.USD","LU0823426480.USD","LU1242518931.SGD","LU0456846285.SGD","LU0516422366.SGD","LU0348825331.USD","LU0039217434.USD","LU0516423174.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661026306","title":"CSPC Pharmaceutical Group Stock Falls 3.5% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2661026306","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661026306?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:31","pubTimestamp":1787301060,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. slid 3.5% to 9.19 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.2% to 26009.46.CSPC Pharmaceutical Group Ltd. closed 21% below its 52-week high of HK$11.63, which the company reached Sept. 9.The stock underperformed when compared to some of its competitors, as Sino Biopharmaceutical Ltd. rose 3.8%, SSY Group Ltd. rose 1.2%, and United Laboratories International Holdings Ltd. rose 3.4%.Trading volume totaled 135.4 million shares, compared to the 50-day average of 98.2 million shares.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0067412154.USD","LU0314109678.HKD","LU1813983027.USD","LU1951186391.HKD","LU1993786604.SGD","LU1226288253.USD","LU1226287792.SGD","IE00BZ08YT58.USD","LU0140636845.USD","IE0008369823.USD","BK1521","LU1226288170.HKD","LU0315179316.USD","LU1152091168.USD","HK0000165453.HKD","LU1328277881.USD","IE00B031HY20.USD","LU1008478684.HKD","LU1226287529.USD","LU1152091754.HKD","LU1226287875.USD","LU1960683339.HKD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","01093","LU1807302812.USD","LU0501845795.SGD","BK1191","KURE","SG9999004220.SGD","LU2039709279.SGD","LU0880133367.SGD","IE0008368742.USD","IE00B5MMRT66.SGD","LU0072913022.USD","BK1515","IE00BZ08YS42.EUR","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140941983","title":"美银证券上调石药集团目标价至8.6港元，维持“跑输大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1140941983","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140941983?lang=en_us&edition=fundamental","pubTime":"2026-08-21 15:20","pubTimestamp":1787296819,"startTime":"0","endTime":"0","summary":"美银证券最新发布的研究报告显示，石药集团（01093）今年上半年总收入及应占净利润分别同比增长40.1%和139.2%，达到186亿元人民币和61亿元人民币。仅就第二季度而言，该集团总收入同比攀升93.8%至121亿元人民币，应占净利润同比大幅增长389.3%至52亿元人民币。基于上述业绩表现，美银证券将石药集团2026至2028年的净利润预测分别上调1.9%、2.6%和1.6%，并将目标价从7.6港元提高至8.6港元。然而，由于核心药物恩必普（NBP）面临价格下调压力，该行决定重申对石药集团的“跑输大市”评级。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YR35.GBP","LU1807302812.USD","BK1191","IE0008368742.USD","LU0880133367.SGD","BK1515","LU1226288253.USD","LU1960683339.HKD","LU1226288170.HKD","01093","IE00B031HY20.USD","EWH","LU0067412154.USD","IE00B543WZ88.USD","BK1521","IE00B5MMRT66.SGD","LU0072913022.USD","161027","LU1152091168.USD","LU1993786604.SGD","LU1226287875.USD","LU1226287792.SGD","LU1226287529.USD","LU1328277881.USD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU0315179316.USD","LU0326950275.SGD","LU0314109678.HKD","LU2039709279.SGD","SG9999004220.SGD","KURE","HK0000165453.HKD","LU0140636845.USD","LU1813983027.USD","LU1008478684.HKD","IE0008369823.USD","LU1152091754.HKD","LU1951186391.HKD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661528902","title":"Akeso Says China NMPA Clears Phase I Trial for B7-H3 ADC Ak157d1 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2661528902","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661528902?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:31","pubTimestamp":1787290275,"startTime":"0","endTime":"0","summary":"Akeso says China NMPA clears Phase I trial for B7-H3 ADC AK157D1 in solid tumorsAkeso secured China NMPA CDE clearance to start a Phase I trial of AK157D1, a B7-H3 antibody-drug conjugate, in advanced","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDLc1jnKH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274308.USD","KURE","LU1720050803.USD","LU0348783233.USD","LU2488822045.USD","LU0348827113.USD","LU2778985437.USD","IE00B543WZ88.USD","09926","LU1794554557.SGD","LU0540923850.HKD","LU0634319403.HKD","LU0348766576.USD","LU0348784397.USD","LU0417516902.SGD","LU1961090484.USD","BK1574","LU2399975544.HKD","LU0417516571.SGD","LU0561508036.HKD","LU0348735423.USD","BK1161","IE00B5MMRT66.SGD","LU0417516738.SGD","LU2476274720.SGD","LU0348767384.USD","IE00BPRC5H50.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661252887","title":"Akeso's Ak157d1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2661252887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661252887?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:30","pubTimestamp":1787290258,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nTUA6ZY0XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B543WZ88.USD","LU0417516571.SGD","LU2476274720.SGD","LU1720050803.USD","BK1161","LU2778985437.USD","LU1794554557.SGD","LU0348825331.USD","09926","LU0348766576.USD","LU2476274308.USD","LU0348827113.USD","BK1574","LU0348735423.USD","IE00BPRC5H50.USD","LU2399975544.HKD","LU0561508036.HKD","LU0348784397.USD","LU1961090484.USD","LU0417516738.SGD","LU2488822045.USD","LU0348767384.USD","LU0634319403.HKD","KURE","IE00B5MMRT66.SGD","LU0417516902.SGD","LU0540923850.HKD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159889202","title":"Morgan Stanley Raises CSPC Pharma Target Price to HK$12, Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1159889202","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159889202?lang=en_us&edition=fundamental","pubTime":"2026-08-21 12:14","pubTimestamp":1787285652,"startTime":"0","endTime":"0","summary":"Morgan Stanley has released a research report updating its model for CSPC PHARMA (01093) following the company's second-quarter results. The brokerage has raised its earnings per share estimates for...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YT58.USD","LU1226287792.SGD","IE00B031HY20.USD","LU0326950275.SGD","LU1226287529.USD","SG9999004220.SGD","LU1152091168.USD","LU1993786604.SGD","EWH","LU1960683339.HKD","LU0072913022.USD","IE0008368742.USD","IE00B5MMRT66.SGD","IE0008369823.USD","IE00B543WZ88.USD","LU1951186391.HKD","IE00BZ08YR35.GBP","LU2039709279.SGD","LU1152091754.HKD","LU1807302812.USD","LU1226288170.HKD","LU1008478684.HKD","LU0314109678.HKD","BK1521","01093","LU1328277881.USD","LU0880133367.SGD","IE00BZ08YS42.EUR","BK1515","LU0501845795.SGD","LU0067412154.USD","LU1813983027.USD","KURE","LU0315179316.USD","LU1226287875.USD","LU1226288253.USD","LU0140636845.USD","HK0000165453.HKD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145981825","title":"Moderna's Personalized mRNA Vaccine Achieves First Success, Chinese Innovators Line Up","url":"https://stock-news.laohu8.com/highlight/detail?id=1145981825","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145981825?lang=en_us&edition=fundamental","pubTime":"2026-08-21 11:56","pubTimestamp":1787284582,"startTime":"0","endTime":"0","summary":"The success of Moderna's Phase 3 trial has delivered the first pivotal proof-of-concept that mRNA technology can work in oncology, redirecting market attention toward Chinese biotech firms actively...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159646","KURE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}